DS-6051b is primarily investigated for its potential in cancer treatment, particularly targeting tumors with specific genetic alterations. It is a small molecule inhibitor designed to block certain tyrosine kinases, which are enzymes that play a critical role in signaling pathways driving cancer cell growth and survival. By inhibiting these kinases, DS-6051b aims to disrupt the proliferation and survival of cancer cells, especially those with NTRK gene fusions or ROS1 mutations, which are often implicated in various solid tumors. Its application is being explored in clinical trials to assess efficacy and safety in patients with advanced or metastatic cancers, offering a potential therapeutic option for those with limited treatment alternatives. Additionally, research is ongoing to determine its effectiveness in combination with other therapies to enhance overall treatment outcomes.